Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
about
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsRecent advances in the management of Hodgkin lymphomaNovel immunotherapies in lymphoid malignanciesNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyNucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingCustomized targeted therapy in Hodgkin lymphoma: hype or hope?Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfallsHerpesvirus exploitation of host immune inhibitory pathwaysNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewPD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse ModelRecent insights in the pathogenesis of post-transplantation lymphoproliferative disordersPembrolizumab in classical Hodgkin's lymphomaComprehensive molecular characterization of gastric adenocarcinomaPD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaThe Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.Immunotherapy in hematologic malignancies: past, present, and future.Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Immune checkpoint blockade for hematologic malignancies: a reviewCheckpoint inhibitors in hematological malignanciesEmerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Pathobiology of hodgkin lymphoma.Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphomaEBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In VitroEBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.Several immune escape patterns in non-Hodgkin's lymphomas.Microenvironment abnormalities and lymphomagenesis: Immunological aspects.RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.Targetable genetic features of primary testicular and primary central nervous system lymphomas.Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphomaHigh PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist.The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patientsPD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
P2860
Q26745842-D06BFECC-7C0B-4025-BBD7-86A4B77FA1B8Q26751214-02B5D175-6B65-4B07-969B-DEA5425A2AC7Q26777394-CCF0261C-0385-47FB-9F83-DC484C3643AFQ26782270-9596ED56-B17B-4498-AB7E-54F28072E453Q26825644-71ECF843-1612-4C02-BAAD-1BD79754D8D5Q27002554-1743024D-6221-4D87-B678-77C9AC98320AQ27004241-EDCA8CB9-1DC7-40FF-8C6D-47103F5E9B6FQ27013680-D65C0A21-4D9D-4F1F-B988-A5ED2B8E93ADQ27304386-A28E7A2B-39F9-47BC-A8DD-71849D01578EQ27313748-B09FFD05-31DE-4D4C-A537-4E14CF010353Q28075701-E4983734-D090-4CA2-A216-DB73771CC939Q28079273-E4FA49F7-2A63-41CE-A428-F4E2C9A15594Q28244985-FB94F70F-5C26-4A9C-BED9-749179431642Q29620878-271DDA38-91E6-45B9-A4F6-9B2E61F7AC38Q30278553-1CC3CA80-C4ED-4E1C-9D51-87B78A11975BQ30916013-8D3DEBFD-F13B-47E9-9003-629B0BC39A79Q33593865-95F3E9C6-1F0C-4A26-A09D-06C8EC374211Q33638083-E8ED72F4-D5E4-4312-925F-4AECB1877999Q33645590-491B8D36-4387-428A-A2EE-A787F23407E8Q33651495-74AFCC8E-1857-43FF-BF36-06F8DF176FB2Q33704061-B6A9B05D-76A9-45E7-9694-769054A9BFE4Q33778402-19610333-6AD8-49B8-9FEF-1393FE56F105Q34141476-9DB3380C-35B1-462C-A3AE-211F7FE58A68Q35067875-896F5D15-9152-4192-9930-8E6DBA505030Q35770856-4D1FF249-9EA3-498D-A5D7-494BAE8C1E74Q35953524-765BBA97-B045-4214-99D8-4650E6C6D544Q36060357-B9973053-D9A7-49D0-8F7B-04624164BD1DQ36118020-4EDB6E71-E2D4-406E-BB9D-A16C87CC7B50Q36193035-0F345C4F-DA65-4921-8BBB-63E370E5AF65Q36253967-66C76F7D-F885-4805-A31A-69AF1122EFFCQ36356089-671288C0-6FCA-49D4-AC16-8284D416CEFDQ36522770-06B98B9A-E9EC-4202-9B67-BB36BBB7393BQ36596879-B065F6EB-120A-4FB0-84B1-E1D740F47A38Q36598782-FB60F66A-6ACD-43D1-A274-9A5031AC9CF7Q36628291-8D007910-0740-4EF1-BFE5-34F01A192028Q36725110-A8A51A5B-E1BB-40CD-85D0-473D27FD1A71Q36844129-5474843F-3B04-48EA-BC2D-534120AC22A0Q36892616-8962D827-3AC7-4C21-80C6-070091BF51AEQ37140496-5BC052E6-3DF9-4D7E-80BF-E91CC06B7696Q37340738-D33FF4F4-2343-4969-B3D4-3159E3BFCFCB
P2860
Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Constitutive AP-1 activity and ...... ications for targeted therapy.
@ast
Constitutive AP-1 activity and ...... ications for targeted therapy.
@en
type
label
Constitutive AP-1 activity and ...... ications for targeted therapy.
@ast
Constitutive AP-1 activity and ...... ications for targeted therapy.
@en
prefLabel
Constitutive AP-1 activity and ...... ications for targeted therapy.
@ast
Constitutive AP-1 activity and ...... ications for targeted therapy.
@en
P2093
P2860
P1476
Constitutive AP-1 activity and ...... ications for targeted therapy.
@en
P2093
Donna Neuberg
Evan O'Donnell
Jing Ouyang
Margaret A Shipp
Michael R Green
Papiya Sinha
Przemyslaw Juszczynski
Scott Rodig
P2860
P304
P356
10.1158/1078-0432.CCR-11-1942
P407
P577
2012-01-23T00:00:00Z